Resources | Reports Overview | Research Report

Kalorama Information

Anti Infectives, Vol II: Antibacterials

Antibacterial drugs have turned bacterial infections into treatable ailments rather than the life-threatening conditions they once were. But the effectiveness of many antibiotics is being reduced as more and more types of bacteria become resistant to them. Because of antibiotic resitance and other changing dynamics, knowledge of issues and trends is necessary to operate the antibacterials market.
Kalorama's Anti-Infectives, Vol. II: Antibacterials provides extensive detail on the anti-bacterial market, including the following critical trends:

Drug resistance and Interactions
Antibiotic Abuse
Antibiotic Cycling
Addressing Market Trends
Antibiotic Use in Agriculture
Antibiotic Education
Children and Bacterial Resistance
The Elderly and Bacterial Resistance
Compromised Individuals and Bacterial Resistance
Screening Hospital Patients
Side Effects of Antibiotics
Partnerships and Alliances
Environment and Drug Resistance
Methicillin Resistant Staphylococcus Aureus

In this, the second volume of Kalorama Information's Anti-Infective Markets series, the antibacterial drug market is broken down into seven general categories based on drug class:

cephalosporins
macrolides
penicillins
quinolones
sulfonamides
tetracyclines
other misc. antibiotics

There is a significant trend shift occuring in the antibacterials market since Kalorama Information's last edition in 2005. Anti-Infectives Vol. II: Antibacterials covers that shift in detail. For each marketplace segment, Market Size, Growth and Share are provided, and revenue is forecasted to 2011 are provided. Current products are discussed and new pipeline products are assessed. In total, over 100 Tables and Figures provide accessible data on this growing market, a depth of coverage unsurpassed by any competitive study.

The following companies are profiled as part of this report:

Abbott Laboratories
AstraZeneca
Bayer Schering Pharma
Cubist Pharmaceuticals
Daiichi Sankyo
GlaxoSmithKline
Johnson & Johnson Group
King Pharmaceuticals
Merck & Company, Inc.
Pfizer, Inc.
Roche
Sanofi-Aventis
Wyeth